Ole Kleist Jeppesen
Ole Kleist Jeppesen publishes mostly in Endocrinology, Diabetes and Metabolism, Molecular Biology and Pulmonary and Respiratory Medicine, on topics such as Diabetes Treatment and Management, Metabolism, Diabetes, and Cancer and Bariatric Surgery and Outcomes.
- World rank
- #364,117 of 7,710,434 ranked researchers
- Rank in Denmark
- #2,636 of 43,819
- Works
- 54
- Citations
- 5.8k
- Citations per work
- 106.8
What does Ole Kleist Jeppesen research?
Ole Kleist Jeppesen's work is mostly in Medicine (61%), Biochemistry, Genetics and Molecular Biology (17%).
Their six largest subfields, inside their fields and domains; the grey slice is everything else they publish. The interactive view splits every one of their works down to single topics.
The fields and subfields, with their numbers
- Health Sciences3360.8%
- Medicine3360.8%
- Everything else1222.4%
- Life Sciences916.8%
- 1Endocrinology, Diabetes and Metabolism39% of their works
- 2Molecular Biology17% of their works
- 3Pulmonary and Respiratory Medicine8% of their works
- 4Surgery5% of their works
- 5Oncology5% of their works
- 6Pharmacology4% of their works
Research topics
- Diabetes Treatment and Management
- Metabolism, Diabetes, and Cancer
- Bariatric Surgery and Outcomes
- Hyperglycemia and glycemic control in critically ill and hospitalized patients
- Diabetes Management and Research
- Chronic Kidney Disease and Diabetes
- Pharmacology and Obesity Treatment
- Diabetes, Cardiovascular Risks, and Lipoproteins
Which keywords describe Ole Kleist Jeppesen's research?
The keywords of their largest research topics: Glycemic Control, Insulin Therapy, Type 2 Diabetes, Cardiovascular Outcomes, Glucose Control, AMP-Activated Protein Kinase, Metformin and Diabetes.
- Metabolic Syndrome
- Pharmacotherapy
- Glomerular Filtration Rate
- Chronic Kidney Disease
- Hyperglycemia
- Metabolic Surgery
- Lifestyle Intervention
- Cardiovascular Disease
- Diabetes
- AMP-Activated Protein Kinase
- Cardiovascular Outcomes
- Insulin Therapy
- Glycemic Control
- Type 2 Diabetes
- Glucose Control
- Metformin
- Obesity
- Weight Loss
- Bariatric Surgery
- Critical Care
- Anti-Obesity Drugs
- Continuous Glucose Monitoring
- Hypoglycemia
- Insulin Resistance
Size is their works in the topics tagged with each word, from their 8 largest topics. Each links to the topic it comes from most. The words come from the keyword list OpenAlex gives each topic, not from the text of the papers, so a word can appear that none of the papers uses.
All 24 words, with their numbers
- Glycemic Control453 topics
- Insulin Therapy453 topics
- Type 2 Diabetes422 topics
- Cardiovascular Outcomes361 topic
- Glucose Control361 topic
- AMP-Activated Protein Kinase211 topic
- Metformin211 topic
- Diabetes133 topics
- Obesity133 topics
- Cardiovascular Disease113 topics
- Weight Loss102 topics
- Lifestyle Intervention92 topics
- Bariatric Surgery61 topic
- Metabolic Surgery61 topic
- Critical Care51 topic
- Hyperglycemia51 topic
- Anti-Obesity Drugs41 topic
- Chronic Kidney Disease41 topic
- Continuous Glucose Monitoring41 topic
- Glomerular Filtration Rate41 topic
- Hypoglycemia41 topic
- Pharmacotherapy41 topic
- Insulin Resistance31 topic
- Metabolic Syndrome31 topic
Where does Ole Kleist Jeppesen work?
Ole Kleist Jeppesen's main affiliation in the publication record is Novo Nordisk (Denmark), Denmark.
How many publications and citations does Ole Kleist Jeppesen have?
OpenAlex counts 54 works and 5,769 citations for Ole Kleist Jeppesen, an h-index of 15, ranking #364,117 of 7,710,434 researchers worldwide on the quality score.
Ranked on field-normalised citation excellence (50%), output (30%) and citations (20%). Counts come from OpenAlex author records, which occasionally merge different people who share a name or split one person into several.
Papers, co-authors, who cited this work and researchers on the nearest topics have tabs of their own, above. Is this your page? Claim it with your ORCID iD, or request a correction or removal.
Discussion
Ask a question or share a note about Ole Kleist Jeppesen. Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.